High expenditure towards the treatment of cancer patients has been hitting the rooftop just like the disease prevalence has. Support, care, and treatment have utterly become super expensive and intensive too. According to a publication in JAMA, this increase is associated to increase in population and aging among people. In fact, it is estimated about $933 billion more was spent on health care in 2013 than in 1996.
Gerald Anderson of Johns Hopkins – Bloomberg School of Public Health linked the high spending to the high health care services. This was in a research dubbed, ‘It’s the Prices, Stupid,’ where along with other scholars this was established. In breaking down the spending on the disease, Joseph Dieleman of the Institute for Health Metrics and Evaluation, University of Washington said that diseases have diverse risk factors that may cause their manifestation and hence their prevalence. He mentioned of deliberate efforts to reduce the spending but listed some hurdles towards the achievement of the same.
Despite efforts to minimize hospital stays, the expenses at the pharmaceuticals, drug prices, and treatment machinery were the biggest challenge. Regardless of the effort, spending still increased. Nonetheless, good willed thoughts and actions are towards reducing the health care spending.
About Eric Lefkofsky
Eric Lefkofsky is a co-founder and Chief Executive Officer of Tempus a healthcare company intuitively making use of technology to make cancer treatment much easier. He has researched and led to the innovation of some disruptive techniques currently being used in cancer diagnosis and treatment. Eric Lefkofsky has also co-founded other companies including, Lightbank, Mediaocean, Uptake, InnerWorkings, and Echo Global Logistics just to mention but a few.
This serial entrepreneur is a graduate of the Law School, Michigan University. Before completing his studies, Eric, alongside a comrade, established a boutique named Brandon Apparel. Eric Lefkofsky is married to Elizabeth Lefkofsky and together give back to the society through the Lefkofsky Foundation and The Giving Pledge. This is motivated by the desire to give human being quality life. He is a regent to the Steppenwolf Theatre Company and Children’s Memorial Hospital, Chicago.
Cancer has been around for many years. It has ravaged the lives of people no matter the age, race or creed. Fortunately, cancer research has come along way, and this research comes on a consistent basis. One of the top cancer research facilities is right here in the United States. Seattle Genetics of Bothell, Washington, is the largest oncology biotechnology company in the world, and it specializes in the development and commercialization of antibody-based therapies. This is a new generation of cancer fighting drugs, and these therapies are delivering great results. The man in charge of this progressive organization is Dr. Clay Siegall. Siegall has been around for many decades in the medical industry. He’s worked with many prominent companies like the National Cancer Institute and Bristol Meyers Squibb. Siegall also serves this organization as one of its founding members back in the late 90s.
Siegall is a man on a mission. Clay also has a brilliant educational background with a Ph.D in Genetics and a B.S. in Zoology. Of course, these degrees came from the institutions of George Washington University and the University of Maryland. The guy is somewhat like a genius thanks to his brilliant way of thinking. Many of his contemporaries say that he is known as a scientist, author and a holder of 15 patents. The success that Seattle Genetics has obtained comes from great research and great leadership. The mission is to save as many lives as possible and thanks to the company’s innovative antibody-drug conjugates, people are getting their lives back in order.
Dr. Clay Siegall does a great job by keeping the public informed on any advancements in the industry. He has an active social media presence as he blogs very regularly. Many of his latest blog posts were about the company’s ADCETRIS drug. This is the flagship medication here, which has made hundred of millions of dollars for Seattle Genetics. Siegall spoke on the many phases of the newer drugs and how well the antitumor drugs were working.
He also spoke on the company’s pipeline and upcoming programs that are due for clinical trials. Siegall has a firm grip on everything that’s happening, and his strong leadership will continue to steer the ship to more success in the future.